Drug Manufacturers - General stocks worldwide, ranked

As of 13 Nov 2026, Astellas Pharma (4503.T) ranks first in Drug Manufacturers - General on MoatMap, with a MoatMap Score of 99/100, among 57 companies in 17 countries worth $200M or more that trade $1M or more a day. A research ranking, not investment advice.

The score reads each company's latest yearly results, so when a whole industry is near the top of its cycle, its companies can rank high together.

Live list, follows each night's scores · scores as of ·How we score stocks

The top 25 Drug Manufacturers - General companies by MoatMap Score

#StockYieldP/EScoreQVMStyle · Activity
1
4503.T
Astellas Pharma Inc.
Japan · $28.7B

Quality 81: F-Score 8/9 and strong free cash flow. Value 76: cheap on EV/EBITDA and cheap on free cash flow. Momentum 66: near its 52-week high and outperforming the market over 6 months.

Yield 3.0%P/E 11.5
99
Score
81
Q
76
V
66
M
Full House
2
BMY
Bristol-Myers Squibb Company
United States · $125.6B

Quality 74: high return on equity and F-Score 8/9. Momentum 70: near its 52-week high and estimates revised up. Value 65: a high yield and cheap on P/E.

Yield 4.0%P/E 13.8
97
Score
74
Q
65
V
70
M
Full HouseDir. sell $678KDeep dive →
3
SAN.PA
Sanofi
France · $99.5B

Momentum 78: near its 52-week high and estimates revised up. Value 70: a high yield and cheap on EV/EBITDA. Quality 62: wide operating margins and F-Score 7/9.

Yield 4.9%P/E 24.2
97
Score
62
Q
70
V
78
M
Full HouseDir. buy $498KDir. sell $4.1M
4
4528.T
Ono Pharmaceutical Co., Ltd.
Japan · $7.5B

Value 77: cheap on free cash flow and cheap on EV/EBITDA. Quality 74: F-Score 8/9 and strong free cash flow. Momentum 61: near its 52-week high and estimates revised up.

Yield 3.2%P/E 14.8
97
Score
74
Q
77
V
61
M
Full House
5
RICHTER.BD
Gedeon Richter PLC
Hungary · $7.3B

Quality 84: wide operating margins and F-Score 8/9. Momentum 70: near its 52-week high and above its moving averages. Value 58: cheap on P/E.

Yield —P/E 10.2
97
Score
84
Q
58
V
70
M
Full House
6
4536.T
Santen Pharmaceutical Co., Ltd.
Japan · $3.6B

Quality 80: low debt and strong free cash flow. Value 68: cheap on free cash flow and cheap on EV/EBITDA. Momentum 61: near its 52-week high and outperforming the market over 6 months.

Yield 1.0%P/E 15.8
97
Score
80
Q
68
V
61
M
Full House
7
ORNBV.HE
Orion Oyj
Finland · $14.5B

Quality 86: ROIC in the top 5% of its sector and high return on equity. Momentum 82: near its 52-week high and estimates revised up. Value 38: far above book value.

Yield 1.8%P/E 21.8
96
Score
86
Q
38
V
82
M
Premium Grower
8
KLBF.JK
PT Kalbe Farma Tbk.
Indonesia · $1.8B

Quality 80: interest well covered and ROIC in the top 10% of its sector. Value 80: cheap on P/E and cheap on EV/EBITDA. Momentum 47: outperforming the market over 6 months but EPS deteriorating.

Yield 2.6%P/E 9.1
96
Score
80
Q
80
V
47
M
Unloved QualityDir. buy $2K
9
1093.HK
CSPC Pharmaceutical Group Limited
China · $12.1B

Quality 73: wide operating margins and interest well covered. Value 71: a high yield and cheap on EV/EBITDA. Momentum 61: quarterly earnings growing and outperforming the market over 6 months.

Yield 3.9%P/E 11.6
95
Score
73
Q
71
V
61
M
Full HouseDir. buy $67.4M
10
OGN
Organon & Co.
United States · $3.6B

Momentum 77: near its 52-week high and EPS improving. Value 69: cheap on free cash flow and cheap on sales. Quality 57: high return on equity but high debt.

Yield 0.6%P/E 17.8
95
Score
57
Q
69
V
77
M
Full HouseDir. sell $200KDeep dive →
11
PNVL3.SA
Dimed S.A. Distribuidora de Medicamentos
Brazil · $461.1M

Value 80: cheap on sales and cheap on free cash flow. Quality 63: high gross profitability and strong free cash flow. Momentum 59: estimates revised up.

Yield 4.2%P/E 12.5
94
Score
63
Q
80
V
59
M
Full House
12
4578.T
Otsuka Holdings Co., Ltd.
Japan · $41.6B

Quality 75: F-Score 7/9 and high gross profitability. Momentum 62: near its 52-week high and above its moving averages. Value 57: mixed.

Yield 1.4%P/E 15.8
91
Score
75
Q
57
V
62
M
Full House
13
ROP.SW
Roche Holding AG
Switzerland · $377.9B

Quality 77: high return on equity and wide operating margins. Momentum 71: near its 52-week high and estimates revised up. Value 43: far above book value.

Yield 2.5%P/E 25.5
89
Score
77
Q
43
V
71
M
Premium GrowerDir. buy $1.0MDir. sell $20.0M
14
PFE
Pfizer Inc.
United States · $171.2B

Momentum 76: EPS improving and near its 52-week high. Value 62: a high yield and cheap on EV/EBITDA. Quality 52: wide operating margins but high debt.

Yield 5.9%P/E 42.0
89
Score
52
Q
62
V
76
M
Full HouseDir. buy $3.0MDir. sell $135K
15
REC.MI
Recordati Industria Chimica e Farmaceutica S.p.A.
Italy · $12.5B

Momentum 72: near its 52-week high and estimates revised up. Quality 72: high return on equity and wide operating margins. Value 48: far above book value.

Yield 1.3%P/E 22.4
89
Score
72
Q
48
V
72
M
Premium GrowerDir. buy $26.7MDeep dive →
16
ABBV
AbbVie Inc.
United States · $504.8B

Momentum 78: quarterly earnings growing and near its 52-week high. Quality 76: wide operating margins and high return on equity. Value 35: expensive on P/E.

Yield 2.4%P/E 50.1
88
Score
76
Q
35
V
78
M
Premium GrowerDir. sell $8.2M
17
AMGN
Amgen Inc.
United States · $237.5B

Momentum 80: near its 52-week high and outperforming the market over 6 months. Quality 71: high return on equity and wide operating margins. Value 38: far above book value.

Yield 2.2%P/E 26.7
88
Score
71
Q
38
V
80
M
Premium GrowerDir. sell $4.1MDeep dive →
18
VIRP.PA
Virbac SA
France · $3.3B

Quality 74: high gross profitability and ROIC in the top 15% of its sector. Momentum 64: near its 52-week high and estimates revised up. Value 52: little or no yield.

Yield 0.4%P/E 19.3
88
Score
74
Q
52
V
64
M
Full House
19
MARKSANS.NS
Marksans Pharma Limited
India · $1.4B

Quality 81: ROIC in the top 10% of its sector and high return on equity. Momentum 73: above its moving averages and outperforming the market over 6 months. Value 36: little or no yield.

Yield 0.3%P/E 24.6
88
Score
81
Q
36
V
73
M
Premium Grower
20
NOVO-B.CO
Novo Nordisk A/S
Denmark · $172B

Quality 76: ROIC in the top 5% of its sector and high return on equity. Value 63: a high yield and cheap on P/E. Momentum 48: estimates revised up but EPS deteriorating.

Yield 4.3%P/E 10.6
87
Score
76
Q
63
V
48
M
Unloved QualityDeep dive →
21
GSK.L
GSK plc
United Kingdom · $101.6B

Quality 73: F-Score 9/9 and high return on equity. Value 65: a high yield and cheap on free cash flow. Momentum 48: near its 52-week high but quarterly earnings shrinking.

Yield 3.6%P/E 17.7
86
Score
73
Q
65
V
48
M
Unloved QualityDir. buy $2.0MDir. sell $3.3MDeep dive →
22
GRF.MC
Grifols, S.A.
Spain · $7.8B

Value 67: cheap on sales and cheap on free cash flow. Momentum 65: near its 52-week high and above its moving averages. Quality 51: wide operating margins but high debt.

Yield 0.7%P/E 15.8
84
Score
51
Q
67
V
65
M
Full House
23
NOVN.SW
Novartis AG
Switzerland · $295.2B

Quality 73: F-Score 8/9 and wide operating margins. Momentum 68: near its 52-week high and estimates revised up. Value 41: far above book value.

Yield 2.8%P/E 31.9
83
Score
73
Q
41
V
68
M
Premium GrowerDir. sell $8.1M
24
LLY
Eli Lilly and Company
United States · $1.1T

Momentum 82: near its 52-week high and estimates revised up. Quality 80: ROIC in the top 5% of its sector and high return on equity. Value 18: far above book value.

Yield 0.5%P/E 43.9
82
Score
80
Q
18
V
82
M
Premium GrowerDir. sell $25.8MDeep dive →
25
600713.SS
Nanjing Pharmaceutical Group Company Limited
China · $957.1M

Momentum 69: outperforming the market over 6 months and near its 52-week high. Value 68: cheap on sales and below book value. Quality 44: ROIC in the top 25% of its sector but high debt.

Yield 3.2%P/E 12.4
82
Score
44
Q
68
V
69
M
Second Wind

Ranked by MoatMap Score, the 0 to 100 score of Quality, Value and Momentum, among companies worth $200M or more that trade $1M or more a day, one line per company. Director dealings are director purchases and sales filed in the last 180 days, where MoatMap carries the market's filings.